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Growth and Tolerance of Preterm Infants Fed a New
Extensively Hydrolyzed Liquid Human Milk Fortifier
Jae H. Kim, yGary Chan, zRichard Schanler, §Sharon Groh-Wargo, jjBarry Bloom,
Reed Dimmit, #Larry Williams, #Geraldine Baggs, and #Bridget Barrett-Reis
ABSTRACT
Objectives: This study was a comparison of growth and tolerance in
premature infants fed either standard powdered human milk fortifier
(HMF) or a newly formulated concentrated liquid that contained extensively
hydrolyzed protein.
Methods: This was an unblinded randomized controlled multicenter
noninferiority study on preterm infants receiving human milk (HM)
supplemented with 2 randomly assigned HMFs, either concentrated
liquid HMF containing extensively hydrolyzed protein (LE-HMF) or a
powdered intact protein HMF (PI-HMF) as the control. The study
population consisted of preterm infants 33 weeks who were enterally
fed HM. Infants were studied from the first day of HM fortification until day
29 or hospital discharge, whichever came first.
Results: A total of 147 preterm infants were enrolled. Noninferiority was
observed in weight gain reported in the intent-to-treat (ITT) analysis was
18.2 and 17.5 g  kg1  day1 for the LE-HMF and PI-HMF groups,
respectively. In an a priori defined subgroup of strict protocol followers
(n¼ 75), the infants fed LE-HMF achieved greater weight over time than
those fed PI-HMF (P¼ 0.036). The LE-HMF group achieved greater linear
growth over time compared to the PI-HMF (P¼ 0.029). The protein intake
from fortified HM was significantly higher in the LE-HMF group compared
with the PI-HMF group (3.9 vs 3.3 g  kg1  day1, P< 0.0001). Both
fortifiers were well tolerated with no significant differences in overall
morbidity.
Conclusions: Both fortifiers showed excellent weight gain (grams per
kilograms per day), tolerance, and low incidence of morbidity outcomes
with the infants who were strict protocol followers fed LE-HMF having
improved growth during the study. These data point to the safety and
suitability of this new concentrated liquid HMF (LE-HMF) in preterm
infants. Growth with this fortifier closely matches the recent
recommendations for a weight gain of >18 g  kg1  day1.
Key Words: breast-feeding, growth, human milk fortifier, preterm infants
(JPGN 2015;61: 665–671)
What Is Known
 Powdered infant milk products cannot be sterilized
and is a source of bacterial infection.
 Very-low-birth-weight infants often require more
protein than presently can be provided with conven-
tional human milk fortifiers.
 A liquid fortifier with higher protein than conven-
tional fortifiers is desirable to increase safety and
improved growth.
What Is New
 A liquid human milk fortifier that is based on exten-
sively hydrolyzed bovine casein with higher amounts
of total protein than powder human milk fortifiers
confers equal to improved growth to very-low-birth-
weight infants
 Use of this new liquid fortifier provides sterility with-
out any increase in feeding intolerance or short-term
adverse effects.
H uman milk (HM) is a source of essential nutrients andimmunologic factors for the preterm infant, but alone it is
not sufficient nutritionally to meet the high demands of the rapidly
growing infant. Human milk fortifiers (HMFs) are nutritional
supplements designed to increase total energy, protein, and micro-
nutrient delivery to preterm infants. The primary benefits of HM
fortification have been improved growth, bone mineralization, and
protein status such as blood urea nitrogen (BUN) (1–5).
Increasing survival and improving growth of the preterm
infant to avoid extrauterine growth restriction have resulted in
demands for protein that present powdered HMF may not achieve.
Received February 21, 2015; accepted October 12, 2015.
From the University of California, San Diego-Rady Children’s Hospital
of San Diego, San Diego, the yUniversity of Utah, Salt Lake City, the
zCohen Children’s Medical Center of New York, New Hyde Park, the
§Case Western Reserve University, MetroHealth Medical Center, Cleve-
land, OH, the jjWesley Medical Center, Wichita, KS, the University of
Alabama, Birmingham, and #Abbott Nutrition, Columbus, OH.
Address correspondence and reprint requests to Jae H. Kim, MD, PhD,
University of California, San Diego, 200 W Arbor Dr, MPF 1140, San
Diego, CA 92103 (e-mail: neojae@ucsd.edu).
www.clinicaltrials.gov registration number: NCT01373073.
This study was funded by Abbott Nutrition.
J.H.K., B.B., G.C., R.S. and S.G.-W. received research funds from the study
sponsor, Abbott Nutrition, to conduct the study. J.H.K. is on the speakers’
bureaus for Abbott Nutrition, Mead Johnson Nutrition, Nestle Nutrition,
Nutricia, and Medela. J.H.K. and R.S. are on the medical advisory board
for Medela. J.H.K. owns shares in PediaSolutions and has provided
medical expert testimony. B.B. received a grant from the Wichita
Medical Research and Education Foundation. G.C. received a research
grant from the University of Utah and has provided medical expert
testimony. S.G.-W. is on the speakers’ bureau of Abbott Nutrition. B.B.-
R., L.W., and G.B. are employees of Abbott Nutrition.
The authors report no conflicts of interest.
Copyright # 2015 by European Society for Pediatric Gastroenterology,
Hepatology, and Nutrition and North American Society for Pediatric
Gastroenterology, Hepatology, and Nutrition. This is an open-access
article distributed under the terms of the Creative Commons Attribution-
NonCommercial-NoDerivatives 4.0 License, where it is permissible to
download and share the work, provided it is properly cited. The work
cannot be changed in any way or used commercially.
DOI: 10.1097/MPG.0000000000001010
ORIGINAL ARTICLE: NUTRITION
JPGN  Volume 61, Number 6, December 2015 665
Although some of these infants may compensate with higher
volume intake, many are unable to consume a sufficient volume
because of pulmonary or other clinical issues and therefore require
further concentration of protein and energy. Higher intake of protein
between 3 and 4 g  kg1  day1 has been associated with improved
growth without complications compared with a lower consumption
of protein (<3 g  kg1  day1) (6). Poor weight gain has been
associated with a higher risk for retinopathy of prematurity and poor
neurodevelopmental outcomes (7,8). It is common practice in the
neonatal intensive care units (NICUs) to add protein modular
(powder or liquid) to the feeding to better meet the protein needs
of the smaller preterm infant. In fact, 42% of the respondents to a
recent survey on nutritional practices in the NICU reported adding
protein to HM (9).
There has been a gradual transition to sterile liquid nutri-
tionals in the neonatal environment during the last decade because
of concerns about powder-based transmission of pathogens such as
Cronobacteria sakasakii (10). The recent development of a liquid
HM–based HMF and a partially hydrolyzed whey-acidified liquid
HMF respond to these concerns (11,12). Unlike powder nutri-
tionals, a liquid HMF may have the advantage of sterility and
simpler liquid-liquid mixing with human milk (HM). One disad-
vantage of a liquid fortifier is volume displacement of HM.
In this study, we evaluated a novel liquid HMF containing
extensively hydrolyzed protein source to determine efficacy and
safety in very-low-birth-weight preterm infants.
METHODS
Study Population
A total of 14NICUs from across the United States participated
in this study, including Tampa, Florida; Wichita, Kansas; Toledo,
Ohio; Salt Lake City, Utah; Birmingham,Alabama; Cleveland, Ohio;
Allentown, Pennsylvania; San Diego, California; Valhalla, New
York; Manhasset, New York; Portland, Oregon; Cleveland, Ohio;
South Bend, India; and Brooklyn, New York. The study population
consisted of preterm infants born at33 weeks’ gestational age with
birth weights ranging from 700 to 1500 g whowere enterally fed HM
in the NICU. Infants identified as eligible for randomization and for
whom consent was obtained were randomly assigned to one of the 2
study regimens. Sealed envelopes containing the subject treatment
group assignment were prepared from randomization schedules that
were computer-generated using a pseudorandom permuted blocks
algorithm. A separate computer-generated randomization schedule
was produced for twins to ensure that eligible twins were both
assigned to the same product. The randomization was block stratified
by birth weight (700–1000 g and 1000–1500g) and sex.
Eligibility criteria included appropriate intrauterine growth
and maternal intent to provide breast milk during the study. The use
of donor HM was not permitted during the study period unless
indicated by the clinical staff or PI but could have been used in the
first week of life before study initiation. Infants were excluded for
enteral feeds not started within 21 days of life, severe congenital
anomalies, expectant transfer to another facility, 5-minute Apgar
<5, severe intraventricular hemorrhage (grade 3 or 4), mechanical
ventilation, major abdominal surgery, severe asphyxia, and necro-
tizing enterocolitis (NEC). Use of probiotics or postnatal cortico-
steroids was not permitted.
Study Design
This was an unblinded randomized controlled multicenter
study conducted on preterm infants receiving HM supplemented
with 2 randomly assigned HMFs, either a newly formulated
concentrated liquid HMF containing extensively hydrolyzed protein
(Abbott Nutrition, Columbus, OH; LE-HMF) or a conventional
powdered intact protein HMF (Similac Human Milk Fortifier, PI-
HMF, Abbott Nutrition) as control. For every 25 mL of HM, HMF
was added as a 5-mL dose of LE-HMF or 1 single packet of PI-
HMF. Study Day (SDAY) 1 was defined as the first day of HM
fortification and occurred within 72 hours after the subject had
reached an intake of at least 100 mL  kg1  day1 of HM. The
primary study period was from SDAY 1 until SDAY 29 or hospital
discharge, whichever came first. This study was approved by
institutional research ethics board as appropriate at each study sites.
Table 1 shows the key study fortifier differences.
Anthropometric indices (weight, length, and head circum-
ference [HC]), tolerance, serum biochemistries, intake, and mor-
bidity data were assessed. Anthropometric variables and tolerance
outcomes were collected after SDAY 29 if the infant remained on
study HMF.
Weight, length, and HC of infants were measured according
to standardized procedures from SDAY 1 to SDAY 29 or hospital
discharge, whichever came first. Weight measures were taken daily
using the hospital scales (incubator or bedside). Documentation of
scale calibration was reviewed during routine visits. The other
anthropometric measurements were performed weekly. Recumbent
length was obtained with a fixed headboard andmoveable footboard
and HC using a nonstretchable tape.
Feeding tolerance was assessed by variables such as stool
characteristics (bloody, hard, black, and/or watery) and the inci-
dence of feedings withheld because of abdominal distention, gastric
residuals, and vomiting. Any nil per os periods were also collected.
Enteral intake was collected from enrollment to SDAY 29.
Intake of HM (including donor/banked HM) or other enteral feeding
(including supplements such as protein modulars) were recorded.
Although the LE-HMF contained the same amount of energy as the
PI-HMF, it contained higher protein and a different source of
protein. It also contained added lutein, docosahexaenoic acid,
and arachidonic acid.
Blood samples were drawn from each infant by venipuncture
or, if necessary, by heelstick on SDAYs 1, 15, and 29. Serum
electrolytes, bicarbonate, calcium, phosphorus, magnesium, alkaline
phosphatase, BUN, andprealbuminwere analyzed at the hospital site.
ConfirmedNEC (determined by usingmodified Bell staging criteria)
and sepsis were recorded. The occurrence of these and other serious
adverse events was documented throughout the study.
TABLE 1. Approximate nutrient composition of PI-HMF or LE-HMF
added to HM
Nutrient PI-HMF LE-HMF
Energy, cal 100 100
Fat, g 5.2 5.1
CHO, g 10.4 10.1
Protein, g 3 3.6
Source/type of protein Intact whey
protein concentrate
Extensively
hydrolyzed casein
DHA, mg 12 24
Vitamin D, IU 150 150
Calcium, mg 175 153
Phosphorus, mg 98 86
Osmolality, mOsm/kg water 385 450
Lutein, mg

23
Values per 100 calories mixed at a ratio of 1 pkt or 5 mL:25 mL HM (as
fed). CHO¼ carbohydrate; DHA¼ docosahexaenoic acid; HM¼ human
milk; LE-HMF ¼ liquid HMF containing extensively hydrolyzed protein;
PI-HMF¼ powdered intact protein HMF.
Lutein not added to product but available in varying amounts from HM.
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Statistical Analysis
Study data were analyzed on an intent-to-treat (ITT) basis
including all enrolled infants who received study fortifier. Based on
anticipated protocol deviations in this high-risk population, a sub-
groupanalysiswas prospectively planned to analyze data from infants
who strictly adhered to the assigned HMF. The strict protocol
followers (SPFs) were defined a priori as those infants who received
<20% of total energy from sources other than the assigned study
HMF; and<3 consecutive days onmodular supplements (eg, protein
supplements, another study HMF, nonstudy formula, or donor milk)
for at least 2 weeks from SDAY 1 to SDAY 29.
Sample size was calculated to test the hypothesis that
LE-HMF was noninferior to PI-HMF using an equivalence limit
of 1.6 g  kg1  day1 in weight gain per day. With a noninferiority
hypothesis and assuming that the expected difference in means is
zero and the common standard deviation is 2.56 g  kg1  day1, the
total sample size required to have 80% power was 66 subjects who
are SPF (33 per group). The power for this unbalanced sample size
distribution is 83%. Assuming an attrition rate of approximately
46%, the target number for enrollment was 124 subjects (62 per
group). A study designed for noninferiority does not preclude
testing for superiority (13). Weight gain (grams per kilogram per
day) for each subject was calculated by an exponential model that
involved a regression line fit on loge (wt), where wt is weight (in
grams) on each day (13). Weight gain (grams per kilogram per day)
was analyzed using analysis of variance with factors for center and
feeding (primary). Analyses were also made adjusting for sex, birth
weight, and average fortified HM intake (milliliters per kilogram
per day) diluted full strength during the study period. A 95% 1-sided
confidence interval for the difference in means between groups was
used for noninferiority evaluation.
Length (centimeters per week) and HC gains (centimeters per
week) were analyzed using the same models. Weight, length, and
HC collected at 1-week intervals were analyzed with repeated
measures analysis of covariance (ANCOVA) testing effects of
center, feeding, sex, study day, interaction of feeding with sex,
feeding with study day, and covariate birth weight. By time point
analyses of weight, length, and HC using ANCOVA were made
post-hoc using 1-sided tests consistent with a noninferiority design.
Average daily volume enteral intake (milliliters per kilogram
perday)was analyzedusing analysis of variance.Complete blood cell
counts with differential and serum blood biochemistries were ana-
lyzed using repeated measures ANCOVA with covariate SDAY 1
measure.
Outcomes expressed as percent of infants (tolerance, mor-
bidity, and respiratory variables) were analyzed using the Cochran-
Mantel-Haenzsel test stratified by center. The frequencies of occur-
rence of adverse events by system organ class and preferred terms
using MedDRA codes were tabulated and analyzed using Fisher
exact test. Hypothesis testing for this study was done using 2-sided,
0.05 level tests. All analyses were made using SAS version 9.2 (SAS
Institute, Cary, NC) on a computer.
RESULTS
Study Population
A total of 147 subjects were randomized into the study. Of
the 147 subjects, 129 were included in the ITT group, that is, all
randomized subjects who received study HMF. Of those subjects in
the ITT group, 75% completed the study duration (45 PI-HMF, 52
LE-HMF). More than half the infants in the ITT group met the
definition for the SPFs (Fig. 1). The number of days on the assigned
study fortifier was 25 and 29 for the PI-HMF (n¼ 63) and LE-HMF
(n¼ 66) groups, respectively. The median number of days on the
assigned study fortifier for SPF was 29 days for both the PI-HMF
and LE-HMF groups as some extended their use beyond the study
period. Of note, some SPF subjects did not complete the study
duration because they were discharged from the hospital.
Demographic and Other Baseline
Characteristics
Characteristics of the study patients are summarized in
Table 2. There were no statistically significant differences among
study subjects randomized to the PI-HMF or the LE-HMF group in
N = 72
Powder fortifier
(PI-HMF)
N = 63
IIT Group
(30 Strict protocol
followers)
N = 45
Completed study
(25 Strict protocol
followers)
N = 52
Completed study
(41 Strict protocol
followers)
N = 66
IIT Group
(45 Strict protocol
followers)
N = 75
Liquid fortifier
(LE-HMF)
9 Received
no product
9 Received
no product
N = 147
All randomized subjects
FIGURE 1. Disposition of subjects.
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gestational age, sex, race, mode of delivery and multiple birth
status. There were, however, more Hispanic infants in the PI-HMF
as compared to the LE-HMF group (28% vs 13%, P¼ 0.041). In
addition, there were no statistical differences between groups at
birth or SDAY 1 for weight, length, and HC. Furthermore, there
were no differences in clinical history and progression of enteral
feeds. Infants in the 2 feeding groups who were SPF reflect
comparable demographic and baseline characteristics patterns.
Growth
There were no statistical differences in the primary outcome
of weight gain (grams per kilogram per day) during the study period
regardless of whether the statistical analysis was performed on the
ITT group or SPFs. Hence, noninferiority was achieved. Respective
weight gains were 17.5 and 18.2 g  kg1  day1 for PI-HMF and
LE-HMF (Table 3). Likewise in the subgroup (SPF) analysis weight
gains were 18.2 and 18.4 g  kg1  day1 for PI-HMF and LE-HMF.
There was, however, a main feeding effect that was the infants fed
LE-HMF compared with infants fed PI-HMF had increased weight
during the study among SPFs as depicted in Fig. 2A (P¼ 0.036).
When analyzing the data at separate time points the weight at
SDAY 29 was significantly higher in LE-HMF group versus the PI-
HMF group (P¼ 0.024). Likewise, infants in the ITT group fed LE-
HMF had higher weights at SDAYs 15, 22, and 29 than infants fed
PI-HMF whether or not adjusted for differences in ethnicity. The
SPF infants receiving LE-HMF reached 1800 g 7 days sooner than
the infants fed PI-HMF (19 vs 26 days, respectively, P¼ 0.049).
The length and HC gains (centimeters per week) during the
study period revealed no statistical differences between the groups
and met growth targets (Table 3). The infants fed LE-HMF com-
pared with infants fed PI-HMF had increased linear growth during
the study among SPFs as depicted in Fig. 2B (P¼ 0.029). When
analyzing the data at separate time points adjusted for birth length,
the length at SDAY 22 and SDAY 29 were significantly higher in
LE-HMF group versus the PI-HMF group (P< 0.05). HC was not
different between the fortifier groups (Fig. 2C).
Feeding Tolerance and Stool Characteristics
In both the ITT and SPF groups, both fortifiers were well
tolerated with similar number and percentage of infants having
feedings withheld because of abdominal distention, gastric
residuals and/or vomiting. There was no difference in the percen-
tage of infants who were nil per os between the groups (22.7 LE-
HMF, 19 PI-HMF). The stool characteristics in both groups were
similar with no differences in bloody stools, hard stools or black
stools. Loose stools were commonly reported—56% in the PI-HMF
group and 53% in the LE-HMF group—and were considered
normal for infants who are receiving HM as their primary feeding.
Enteral Nutrition
The mean caloric and protein intakes are reported for both
HMF groups. For the SPFs, the average percentage of calories from
fortified HM was 96% in both the PI-HMF and LE-HMF groups.
The mean intake of fortified HM was 116 and 114 kcal  kg1  day1
in the PI-HMF and LE-HMF groups, respectively. The calculated
protein intake from fortified HM was significantly higher in the LE-
HMF group as compared to the PI-HMF group (3.9 vs 3.3 g  kg1 
day1, P< 0.0001). This difference was expected as LE-HMF con-
tains more protein than PI-HMF. Energy intakes were not different
between the groups.
Blood Chemistries
The blood chemistries reported in Table 4 include bicarbon-
ate, BUN, prealbumin, calcium, phosphorus, magnesium, alkaline
phosphatase, and electrolytes. In general, the blood biochemistries
at SDAYs 1, 15, and 29 were within the normal reference ranges for
preterm infants for both the ITT and SPF groups fed milk fortified
with either fortifier (14,15). There were significant differences
between groups in both the ITT and SPF analyses for BUN
TABLE 2. Neonatal and perinatal characteristics of preterm infants
Treatment group

PI-HMF (n¼ 63) LE-HMF (n¼ 66)
Gestational age, wk 28.7 0.2 28.8 0.2
Birth weight, g 1156 24 1193 26
Birth length, cm 37.4 0.3 37.7 0.3
Birth HC, cm 26.1 0.2 26.5 0.2
Male sex, n (%) 35 (56) 36 (55)
Ethnicity: Hispanic, n (%) 17 (28) 8 (13)y
Race, n (%)
White 42 (67) 43 (65)
Black 13 (21) 17 (26)
Asian 1 (2) 1 (2)
Other 7 (11) 3 (5)
White/other 0 (0) 2 (3)
C-section, n (%) 38 (60) 42 (64)
Twin, n (%) 16 (25) 12 (18)
Age at study day 1, d 12.3 0.7 12.8 0.6
Birth class, n (%)
1000 g 16 (24) 12 (19)
>1000 g 66 (76) 63 (81)
LE-HMF¼ liquid HMF containing extensively hydrolyzed protein;
PI-HMF¼ powdered intact protein HMF.
MeanSEM.
yP¼ 0.0407.
TABLE 3. Anthropometric gains
Treatment group

Targeted growthy,zPI-HMF (n¼ 63) LE-HMF (n¼ 66)
Weight gain, g kg1 day1 17.5 0.6 18.2 0.3 >18
Length gain, cm/wk 1.2 0.07 1.2 0.06 >0.9
HC gain, cm/wk 1.0 0.04 1.0 0.05 >0.9
LE-HMF¼ liquid HMF containing extensively hydrolyzed protein; PI-HMF¼ powdered intact protein HMF; HC¼ head circumference.
Intent-to-treat group, n¼ 129.
yEhrenkranz et al (7).
zEhrenkranz et al (30).
Kim et al JPGN  Volume 61, Number 6, December 2015
668 www.jpgn.org
(P< 0.001) and prealbumin (P< 0.01), with both being higher in
the LE-HMF group. Both groups were well within reference ranges
for these parameters. Bicarbonate was significantly higher in the
LE-HMF group only at SDAY1 in the ITT analysis.
Safety and Morbidity Data
In the ITT group, fewer infants discontinued fortifier because
of feeding intolerance in the LE-HMF group as compared to the PI-
HMF group (2% vs 10%, P¼ 0.048). There was a low incidence of
confirmed NEC (1.5% in the LE-HMF group and 3.2% in the PI-
HMF group) and confirmed sepsis (4.5% vs 3.2%, respectively)
DISCUSSION
The purpose of developing LE-HMF was to provide a
concentrated liquid fortifier that would be superior to conventional
powder HMF by virtue of sterility, higher protein concentration,
and absence of intact cow’s-milk protein. An extensively hydro-
lyzed protein source is included to promote feeding tolerance in
preterm infants. The extensively hydrolyzed protein may be toler-
ated better for infants who are sensitive to the intact cow’s-
milk protein.
The primary purpose of the present clinical trial was to assess
whether the new HMF would promote targeted weight gain, with
good tolerance and without association with specific comorbidities
in a noninferiority comparison with a commercially available
powder HMF that has demonstrated safety and efficacy in preterm
infants (13).
Weight gain and linear growth approaching intrauterine rates
are important goals in the management of premature infants. The
mean weight gain for both groups (PI-HMF and LE-HMF)
exceeded the intrauterine growth rate of 15 g  kg1  day1 and
closely matched recent recommendations for a weight gain of>18 g
 kg1  day1 (7). The mean HC gain for both groups also closely
matched recent recommendations for a HC gain of>0.9 cm/wk (7).
This result was not surprising given the excellent weight, length,
and HC gains previously reported in infants fed PI-HMF powder
(13).
Ehrenkranz et al (7) have reported that as the rate of weight
gain increased in hospitalized preterm infants, the incidence of
cerebral palsy, neurodevelopmental impairment, and need for re-
hospitalization decreased significantly. A weight gain rate of>18 g 
kg1  day1 and a HC growth rate of >0.9 cm/wk were associated
with better neurodevelopmental and growth outcomes. Lower quar-
tile growth was associated with the poorest neurodevelopmental
outcomes.
Weight and length differed between the groups. Although
there were no significant differences in mean weight at birth or
SDAY 1, infants receiving LE-HMF had 1/2 lb greater mean
weight than the infants in the PI-HMF group at the end of the
study period. Although the rate of linear growth was not statistically
different, infants in the LE-HMF group had greater achieved linear
growth during the study period. It is possible that the greater weight
and length in the LE-HMF infants was because of the higher number
of infants in this group that adhered to the assigned study feeding.
New expert recommendations suggest that extremely-low-
birth-weight infants (<1000 g birth weight) have higher protein
requirements (3.5–4.5 g/100 kcal) (16). HMFs provide an important
strategy to overcoming nutrient deficits for preterm and low-birth-
weight infants. Differences in the level and ingredient sources of the
macronutrients, especially the protein quantity, in PI-HMF versus
LE-HMF may have contributed to the overall performance of the LE-
HMF group. The higher protein intake in infants receiving LE-HMF
(3.6 g/100 kcal) as compared to PI-HMF (3.0 g/100 kcal) was
likely one of the reasons for the improved growth observed in these
infants. Although infants in the LE-HMF group had higher protein
intakes, energy intakes were not different between the groups.
Preterm infants fed fortified HM have variable rates of
growth at least partly because of differences in intake of calories,
carbohydrates, electrolytes, calcium, phosphate, and protein. The
acid-base status of the preterm infant also, however, affects growth.
In preterm infants the kidney may not tolerate an acid load, leading
to the development of metabolic acidosis. In a recent study, a liquid
acidified HMF caused metabolic acidosis and poor growth in
preterm infants in the NICU (17,18). In another study, Rochow
et al (19) described a commercially available fortifier in Europe that
had to be reformulated because of the development of metabolic
acidosis from an imbalance of electrolytes. The authors recorded a
mean weight gain of only 9.7 g  kg1  day1 and decreased bone
mineralization with metabolic acidosis. No infants in our study
developed metabolic acidosis.
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FIGURE 2. Evaluable analysis: A, weight (in grams); B, length (in
centimeters); C, head circumference (in centimeters). A, Weight
(in grams). Repeated measures analysis main effect, P¼0.036;
post-hoc per time point analysis: SDAY 29, P¼0.024. B, Length (in
centimeters). Repeated measures analysis main effect, P¼0.029;
post-hoc per time point analysis: SDAY 22, P¼0.006, SDAY 29,
P¼0.037. C, Head circumference (in centimeters).
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The LE-HMF protein source may be beneficial for this popu-
lation because it was extensively hydrolyzed casein formulation
without any intact cow’s-milk protein. It has been suggested that a
combination of free amino acids and short chain peptides (di- and tri
peptides) may allow more optimal nitrogen absorption (20,21). Intact
bovine protein powder HMF has an excellent safety record; however,
a recent study by Sullivan et al (11) suggested the possibility that even
in the presence of a HM base diet, the addition of intact bovine protein
powder HMF is associated with higher rates of total and surgical
NEC. The mechanism for the higher NEC risk is not known yet.
Although this study was not powdered for NEC there was no
difference in the NEC or sepsis rates between the infants fed an
intact bovine protein and the extensively hydrolyzed protein. Both
groups had rates lower than previously reported (22–24).
Intact bovine protein has higher associated long-term risk for
allergy and atopy compared with HM-fed infants. Protein intolerance
is seen in premature infants and in term infants (25). Because preterm
infants have a similar risk for allergy and atopy compared with term
infants and in the NICU have presented with symptoms suggestive of
allergic colitis, avoiding intact bovine protein may be a desirable
objective. For preterm infants fed HM the use of an extensively
hydrolyzed protein-based HMF is an appropriate option.
In general, blood chemistries were within normal reference
ranges for preterm infants. The higher BUN and prealbumin seen in
the LE-HMF group can be attributed to the higher protein content of
LE-HMF. These higher values may be indicative of improved
protein nutriture. It should be noted that although BUN is influenced
by renal function and hydration state, all other influences being
equal, it is proportional to protein intake and responds rapidly to
changes in protein intake (4,5,26,27).
Postnatal growth failure remains common in premature
infants. Nearly 25 years ago Kashyap et al showed that even a
small deficit in protein intake impairs both growth in lean body
mass and linear growth (28). In recent years, Arslanoglu et al
reported that addition of protein to preterm feedings of recovering
VLBW infants resulted in significantly improved linear growth
(4,5). This was accomplished by monitoring the BUN level so that
when it was less than 9 mg/dL, increased protein was added to their
feedings. It was observed in the present study that the mean BUN
level fell <9 mg/dL by week 2 in infants receiving PI-HMF;
however, in infants receiving LE-HMF it never fell <9 mg/dL
during the entire study period. Our results, in part, agree with other
investigators that an increased protein-to-calorie ratio in the feeds
of preterm infants will improve linear growth (4,5,9,28). It is
TABLE 4. Blood chemistry data
Characteristics Reference ranges Study day
Treatment group

PI-HMF LE-HMF
Bicarbonate, mEq/Ly 17–24 1 23.27 0.45 (59) 25.05 0.45 (62)
15 24.32 0.50 (49) 25.40 0.39 (58)
29 25.04 0.43 (40) 25.54 0.44 (50)
BUN, mg/dLz 2.5–31.4 1 11.47 0.78 (56) 11.89 1.03 (61)
15 8.30 1.15 (50) 11.72 0.68 (58)
29 5.81 0.38 (40) 9.31 0.53 (49)
Prealbumin, mg/dL§ 7.0–39.0 1 10.05 0.37 (58) 9.69 0.33 (54)
15 10.11 0.37 (47) 11.40 0.41 (46)
29 9.08 0.35 (36) 10.01 0.35 (37)
Calcium, mg/dL 8.0–11.0 1 10.10 0.08 (56) 9.93 0.08 (60)
15 9.93 0.10 (50) 9.95 0.07 (57)
29 9.89 0.09 (40) 9.82 0.06 (49)
Phosphorus, mg/dL 4.2–8.7 1 6.41 0.17 (54) 6.20 0.13 (58)
15 6.71 0.13 (46) 6.50 0.12 (56)
29 6.66 0.10 (40) 6.46 0.12 (47)
Magnesium, mg/dL 1.5–2.1 1 1.90 0.03 (54) 1.88 0.02 (59)
15 1.80 0.03 (47) 1.86 0.03 (55)
29 1.81 0.02 (40) 1.82 0.03 (46)
Alkaline phosphatase, U/L 150–400 1 443.89 24.50 (55) 415.40 15.78 (60)
15 366.13 21.80 (48) 332.68 10.87 (57)
29 335.28 21.84 (40) 342.36 13.10 (47)
Sodium, mEq/L 129–143 1 137.49 0.49 (61) 138.42 0.34 (65)
15 137.46 0.55 (52) 137.56 0.29 (59)
29 139.07 0.41 (41) 138.70 0.40 (50)
Potassium, mEq/L 4.5–7.1 1 5.39 0.11 (61) 5.20 0.09 (65)
15 5.25 0.09 (52) 5.23 0.09 (59)
29 5.25 0.10 (41) 5.06 0.07 (50)
Chloride, mEq/L 100–117 1 104.16 0.60 (58) 104.03 0.55 (63)
15 104.10 0.72 (49) 103.88 0.43 (57)
29 106.00 0.57 (40) 106.14 0.37 (49)
BUN¼ blood urea nitrogen; LE-HMF¼ liquid HMF containing extensively hydrolyzed protein; PI-HMF¼ powdered intact protein HMF; HC¼ head
circumference.
Values are meanSEM (n).
yBicarbonate (mEq/L): (SDAY 1) LE-HMF > PI-HMF, P¼ 0.0419, LSMSE: LE-HMF¼ 24.71 0.56, PI-HMF¼ 23.33 0.62.
zBUN (mg/dL): Feeding main effect: LE-HMF > PI-HMF, P¼ 0.0013, LSMSE: LE-HMF¼ 11.99 0.73, PI-HMF¼ 8.99 0.83.
§ Prealbumin (mg/dL): Feeding main effect: LE-HMF > PI-HMF, P¼ 0.0049, LSMSE: LE-HMF¼ 10.61 0.35, PI-HMF¼ 9.32 0.38.
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becoming increasingly evident that promoting catch-up growth in
the NICU may have implications for long-term development and
health (7,29).
Our study did have several limitations. The study examined
the combined effects of changing both protein content and type
(hydrolyzed vs intact). Future studies may want to capture effects of
changing one of these variables. A number of subjects in this study
did not complete the protocol to SDAY 29. This partially diluted the
effects seen in the ITT groups but still permitted demonstration of
differential effects seen in the SPF subgroup. A larger study design
may improve this in the future. Infants <700 g birth weight were
excluded from this study and therefore the study findings cannot be
readily extrapolated to this vulnerable group. It is expected however
that this group would have higher protein demands than infants in
this study and therefore would be as likely or more to have a
favorable response to higher protein. Although no differences were
seen between both groups for NEC and sepsis the study size was too
small to discern true differences for these outcomes.
CONCLUSIONS
Both fortifiers showed excellent tolerance and a low rate of
morbidity outcomes, with the infants who were SPFs fed LE-HMF
having improved growth. These data confirm the safety and suit-
ability of this new concentrated liquid HMF for preterm infants.
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